Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¸°­ ÆíÆò¼¼Æ÷¾ÏÁ¾¿¡¼­ p53 ´Ü¹é°ú Áõ½Ä¼º ¼¼Æ÷ÇÙÇ׿ø ¹ßÇö¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿¬±¸

An IMMUNOHISTOCHEMICAL STUDY OF p53 PROTEIN AND PROLIFERATING CELL NUCLEAR ANTIGEN EXPRESSION IN ORAL SQUAMOUS CELL CARCINOMA

´ëÇѱ¸°­¾Ç¾È¸é¿Ü°úÇÐȸÁö 1998³â 24±Ç 4È£ p.411 ~ 420
ÀÌÁØÇà, À¯º¸¿µ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÁØÇà (  ) - Àü³²´ëÇб³
À¯º¸¿µ (  ) - Àü³²´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¿Ü°úÇб³½Ç

Abstract

°á·Ð
º» ¿¬±¸´Â ±¸°­ ÆíÆò¼¼Æ÷¾ÏÁ¾¿¡¼­ ÀÓ»óº´±â, º´¸®Á¶Á÷ÇÐÀû ¾Ç¼ºµµ, p53 ´Ü¹é ¹× Áõ½Ä¼º
PCNA Ç¥½ÃÁö¼ö°¡ ¾ÏÁ¾ÀÇ Áõ½ÄÀ̳ª ħÀ± ¶Ç´Â ¿¹Èĸ¦ ³ªÅ¸³»´Âµ¥ ¾ó¸¶³ª À¯¿ëÇÑ°¡¸¦ ¾Ë¾Æ
º¸±â À§ÇÏ¿© ½ÃÇàµÇ¾ú´Ù.
1989³â 9¿ùºÎÅÍ 1997³â 3¿ù±îÁö Àü³²´ëÇб³º´¿ø ±¸°­¾Ç¾È¸é¿Ü°ú¿¡ ³»¿øÇÏ¿© ±¸°­ ÆíÆò¼¼Æ÷
¾ÏÁ¾(SCC)À¸·Î Áø´ÜµÈ 27·Ê(±×Áß 7·Ê´Â Àç¹ß)¸¦ ´ë»óÀ¸·Î ÇÏ¿´°í, À̶§ ºñƯÀ̼º ¿°Áõ¼º »ó
ÇÇÁõ½Ä º´¼Ò 10·Ê¸¦ ´ëÁ¶±ºÀ¸·Î ÇÏ¿´´Ù. ÀÓ»óº´±â¿Í º´¸®Á¶Á÷ÇÐÀû ¾Ç¼ºµµ¸¦ ÃøÁ¤ÇÏ°í p53
´Ü¹é°ú PCNA¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐÀû °Ë»ç¸¦ ½ÃÇàÇÏ¿© p53 ´Ü¹é ¹× PCNA Ç¥½ÃÁö¼ö¸¦ °¢
°¢ ±¸ÇÏ°í À̵éÀ» ºñ±³ ºÐ¼®ÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù.
1. SCC±º 20·ÊÀÇ Æò±Õ ¿¬·ÉÀº 61.2¼¼¿´´Ù. 20·Ê Áß 7·Ê(35%)¿¡¼­ ¼úÈÄ 4°³¿ù À̳»¿¡ Àç¹ß
ÇÏ¿´°í, Àç¹ßµÈ SCC±º¿¡¼­ ¼úÀü°ú ¼úÈÄÀÇ ÀÓ»óº´±â, ¾Ç¼ºÄ¡, p53´Ü¹é ¹× PCNA Ç¥½ÃÁö¼ö
°£¿¡´Â À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù.
2. p53 ´Ü¹é°ú PCNA¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿°»ö °á°ú p53 ´Ü¹éÀº SCC±º 20·ÊÁß 13·Ê
(65%)¿¡¼­, PCNA´Â 20·ÊÁß 16·Ê (80%)¿¡¼­ ¾ç¼º¹ÝÀÀÀ» º¸¿´´Ù.
3. SCC±º¿¡¼­ p53´Ü¹é ¹× PCNA Æò±Õ Ç¥½ÃÁö¼ö´Â 24.71¡¾27.86% ¿Í 41.49¡¾2.51%·Î ´ëÁ¶
±º¿¡ ºñÇØ ³ô¾ÒÀ¸³ª µÎ Ç¥½ÃÁö¼ö °£¿¡´Â À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù(P<0.05).
4. SCC±º¿¡¼­ ¾Ç¼ºÄ¡ Æò±ÕÀº 15.22 0.64¿´°í ¾Ç¼ºÄ¡¿Í Àӻ󺴱⠱׸®°í ¾Ç¼ºÄ¡¿Í p53 ´Ü¹é
¹× PCNA Ç¥½ÃÁö¼ö °£¿¡´Â À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù.
5. SCC±º°ú Àç¹ßµÈ SCC±º¿¡¼­ p53´Ü¹é ¹× PCNA Ç¥½ÃÁö¼ö, ¾Ç¼ºÄ¡ °£¿¡ Åë°èÇÐÀû À¯ÀǼº
Àº ¾ø¾ú´Ù.
ÀÌ»óÀÇ °á°ú´Â p53 ´Ü¹é°ú PCNA°¡ ¾ÏÁ¾ÀÇ Áõ½ÄÀ̳ª ħÀ±ÀÇ ÁöÇ¥·Î¼­ ÇÑ°è°¡ ÀÖÀ¸¸ç ¾ÕÀ¸
·Î ÀÌ¿¡ ´ëÇÑ ´õ ¸¹Àº ¿¬±¸°¡ ÇÊ¿äÇÔÀ» ½Ã»çÇÏ¿´´Ù.
#ÃÊ·Ï#
The present study was aimed at investigationg the usefulness of clinical stage, degree
of histopatphological malignancy, p53 protein and PCNA labelded indices in deciding the
prognosis, proliferation and infiltration of oral squamous cell carcinoma (SCC).
Twenty-seven cases of SCC (seven were recurrent cases) were analyzed and 10 cases
of non-specific inflammatory lesion served as control. Malignant scores were obtained
with the Anneroth's classification. Proliferative activity of SCC in oral cavity was
examined by means of proliferaling cell nuclear antigen (PCNA) and p53 protein
immunostaining using DO7, PC10 (Novostra Co., U.K.) as primary antibody and
biotinylated linked antibody (LSAB kit, Dako Co., U.S.A.) as secondary antibody. The
labeled indices of PCNA and p53 were calculated by computer image analysis system in
400 multiplication microscopic fields. Results obtained were as follows :
1. The mean age of SCC group was 61.2 years. Seven of 20 cases had recurrence in 4
months after the operation, in which no significant correlation were noted between
pre-and postoperative clinical stage, malignant scores, p53 protein and PCNA indices.
2. Positive immunostaining was noted in 65% (13 of 20 cases) on p53 protein and in
80% (16 of 20 cases) on PCNA.
3. Mean p53 protein and PCNA labeled indices were 24.71¡¾27.86% and 41.49¡¾2.51% in
SCC group. They were high in SCC group than those in control group, although there
was no signficant correlation between the two indices.
4. Mean malignant score was 15.22 0.64 in SCC group. There was no correlation
between malignant score and clinical stage, and between malignant score and p53
protein or PCNA indices.
5. There was no signficant correlation between SCC and recurrent SCC group in
malignant scores, p53 protein or PCNA indices.
These results suggest that p53 and PCNA labeled indices have only limited usefulness
in deciding the prognosis, proliferation and infiltration of oral squamous cell carcinoma.

Å°¿öµå

squamous cell carcinoma; immunohistochemical study.;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed